東華大學圖書館 |

Accelerating Drug Development with Health-Consumer-Contributed Data and Heterogeneous Network Mining.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Accelerating Drug Development with Health-Consumer-Contributed Data and Heterogeneous Network Mining./
作者:	Zhao, Mengnan .
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
面頁冊數:	147 p.
附註:	Source: Dissertations Abstracts International, Volume: 81-08, Section: B.
Contained By:	Dissertations Abstracts International81-08B.
標題:	Information science. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=27669234
ISBN:	9781392519547

Accelerating Drug Development with Health-Consumer-Contributed Data and Heterogeneous Network Mining.
Zhao, Mengnan .

Accelerating Drug Development with Health-Consumer-Contributed Data and Heterogeneous Network Mining. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 147 p.

Source: Dissertations Abstracts International, Volume: 81-08, Section: B.

Thesis (Ph.D.)--Drexel University, 2019.

This item must not be sold to any third party vendors.

New drug development is a time-consuming, high-investment, and high-risk process. It usually takes more than ten years to bring a new medication to market and costs the pharmaceutical companies an average of $1.2 billion during the procedure. As a result, taking drugs that have been developed for one disease and "repositioning" them to another disease is becoming more and more common and an increasingly important strategy in both industry and academia. Current drug repositioning researches can be categorized as biological experimental methods and computational methods. The fast development of biomedical knowledge bases and computational capabilities has elevated a number of computational drug repositioning approaches, with less investment in time and cost compared with experimental approaches. Additionally, another important starting point for drug repositioning is off-label drug use. The detection of off-label drug uses in clinical practice can provide relevant hypotheses for drug repositioning and drug development, meanwhile, the findings in drug repositioning also provide possible off-label use opportunities. In this dissertation, we focus on both off-label drug use and drug repositioning to accelerate the drug development. With consideration of the insufficient utilization of unstructured biomedical data especially the contents contributed by health consumers, we employed health-consumer-contributed data for the topics. Specifically, for off-label drug use, we develop an automated method to detect off-label drug use from the heterogeneous healthcare network based on meta-path mining. In order to find better ways to represent the relationships between medical entities, we improve the method by introducing word embedding models to measure those associations on the basis of association rule mining. In order to deal with the sparsity and missing data problem in user-generated contents, we furtherly employ tensor decomposition techniques for detecting off-label drug-disease relationships. Experiment results show that the proposed approaches could identify off-label drug uses from health-consumer-contributed data effectively and accurately. Especially, when incorporating word embedding models and tensor decomposition, the models achieve better results. For drug repositioning, we propose a systematic method to identify repositioning drugs from health-consumer-contributed data by using the adverse drug reaction (ADR)-based repositioning strategy and heterogeneous network mining approaches. Based on the constructed heterogeneous healthcare network, we develop path-mining approaches to extract the significant associations between ADRs and diseases and then identify the novel associations between drugs and diseases for repositioning opportunity. To better understand the repositioning results and examine the computational repositioning approach, we conduct detailed literature review and case studies for a specific disease, Parkinson's Disease (PD). Additionally, in order to resolve the challenge of extracting ADR entities from health-consumer-contributed texts and improve the performance of drug repositioning detection, we utilize bidirectional long short-term memory (LSTM) models to recognize ADRs first and then use the expanded vocabulary to construct and mine the heterogeneous healthcare network. Experiment results show that ADRs are effective intermediaries to reveal drug-disease associations and the proposed approaches could suggest quite potential repositioning drug candidates.

ISBN: 9781392519547Subjects--Topical Terms:

554358
Information science.
Subjects--Index Terms:

Drug repositioning

Accelerating Drug Development with Health-Consumer-Contributed Data and Heterogeneous Network Mining.
LDR:04903nmm a2200457 4500 001 2271049
005 20201008063051.5
008 220629s2019 ||||||||||||||||| ||eng d
020 $a 9781392519547
035 $a (MiAaPQ)AAI27669234
035 $a AAI27669234
040 $a MiAaPQ $c MiAaPQ
100 1 $a Zhao, Mengnan . $3 3548450
245 1 0 $a Accelerating Drug Development with Health-Consumer-Contributed Data and Heterogeneous Network Mining.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 147 p.
500 $a Source: Dissertations Abstracts International, Volume: 81-08, Section: B.
500 $a Advisor: Yang, Christopher C.
502 $a Thesis (Ph.D.)--Drexel University, 2019.
506 $a This item must not be sold to any third party vendors.
520 $a New drug development is a time-consuming, high-investment, and high-risk process. It usually takes more than ten years to bring a new medication to market and costs the pharmaceutical companies an average of $1.2 billion during the procedure. As a result, taking drugs that have been developed for one disease and "repositioning" them to another disease is becoming more and more common and an increasingly important strategy in both industry and academia. Current drug repositioning researches can be categorized as biological experimental methods and computational methods. The fast development of biomedical knowledge bases and computational capabilities has elevated a number of computational drug repositioning approaches, with less investment in time and cost compared with experimental approaches. Additionally, another important starting point for drug repositioning is off-label drug use. The detection of off-label drug uses in clinical practice can provide relevant hypotheses for drug repositioning and drug development, meanwhile, the findings in drug repositioning also provide possible off-label use opportunities. In this dissertation, we focus on both off-label drug use and drug repositioning to accelerate the drug development. With consideration of the insufficient utilization of unstructured biomedical data especially the contents contributed by health consumers, we employed health-consumer-contributed data for the topics. Specifically, for off-label drug use, we develop an automated method to detect off-label drug use from the heterogeneous healthcare network based on meta-path mining. In order to find better ways to represent the relationships between medical entities, we improve the method by introducing word embedding models to measure those associations on the basis of association rule mining. In order to deal with the sparsity and missing data problem in user-generated contents, we furtherly employ tensor decomposition techniques for detecting off-label drug-disease relationships. Experiment results show that the proposed approaches could identify off-label drug uses from health-consumer-contributed data effectively and accurately. Especially, when incorporating word embedding models and tensor decomposition, the models achieve better results. For drug repositioning, we propose a systematic method to identify repositioning drugs from health-consumer-contributed data by using the adverse drug reaction (ADR)-based repositioning strategy and heterogeneous network mining approaches. Based on the constructed heterogeneous healthcare network, we develop path-mining approaches to extract the significant associations between ADRs and diseases and then identify the novel associations between drugs and diseases for repositioning opportunity. To better understand the repositioning results and examine the computational repositioning approach, we conduct detailed literature review and case studies for a specific disease, Parkinson's Disease (PD). Additionally, in order to resolve the challenge of extracting ADR entities from health-consumer-contributed texts and improve the performance of drug repositioning detection, we utilize bidirectional long short-term memory (LSTM) models to recognize ADRs first and then use the expanded vocabulary to construct and mine the heterogeneous healthcare network. Experiment results show that ADRs are effective intermediaries to reveal drug-disease associations and the proposed approaches could suggest quite potential repositioning drug candidates.
590 $a School code: 0065.
650 4 $a Information science. $3 554358
650 4 $a Bioinformatics. $3 553671
650 4 $a Pharmaceutical sciences. $3 3173021
650 4 $a Biochemistry. $3 518028
650 4 $a Pharmacology. $3 634543
650 4 $a Biomedical engineering. $3 535387
650 4 $a Health sciences. $3 3168359
650 4 $a Biostatistics. $3 1002712
650 4 $a Information technology. $3 532993
650 4 $a Health care management. $3 2122906
653 $a Drug repositioning
653 $a Healthcare informatics
653 $a Heterogeneous network mining
653 $a Off-label drug use
653 $a Online health community
690 $a 0723
690 $a 0572
690 $a 0566
690 $a 0489
690 $a 0541
690 $a 0487
690 $a 0419
690 $a 0769
690 $a 0308
690 $a 0715
710 2 $a Drexel University. $b Information Studies (College of Computing and Informatics). $3 2104098
773 0 $t Dissertations Abstracts International $g 81-08B.
790 $a 0065
791 $a Ph.D.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=27669234